SAFETY OF LONGTERM THERAPY WITH WARFARIN: POSSIBILITY OF TREATMENT RENEWING AFTER HEMORRHAGIC COMPLICATIONS

Por E. S. Kropacheva
Publicado em 2016-01-01

SAFETY ISSUES IN THE TREATMENT OF PATIENTS TAKING DABIGATRAN

Por E. S. Kropacheva
Publicado em 2016-07-01

SAFETY OF THERAPY AND PATRONAGE SYSTEM IN PATIENTS WHO RECEIVE WARFARIN

Por E. S. Kropacheva
Publicado em 2015-12-01

Intracardiac thrombosis: frequency, risk factors and place of oral anticoagulants in treatment

Por E. S. Kropacheva
Publicado em 2020-06-01

ASPECTS OF MULTICOMPONENT THERAPY AND PERIOPERATIVE TACTICS IN A PATIENT WITH ATRIAL FIBRILLATION RECEIVING RIVAROXABAN THERAPY. CLINICAL OBSERVATION

Por O. A. Zemlyanskaya, E. S. Kropacheva
Publicado em 2019-06-01

SELECTING AN OPTIMAL LONG-TERM ANTICOAGULANT THERAPY FOR A PATIENT WITH ATRIAL FIBRILLATION AND RECURRENT MINOR HEMORRHAGE. CLINICAL FOLLOW-UP

Por E. S. Kropacheva, E. P. Panchenko
Publicado em 2017-05-01

Aspects of anticoagulant therapy in patients with atrial fibrillation in the light of updated guidelines of the European society of cardiology 2020: the position of dabigatran

Por E. S. Kropacheva, E. P. Panchenko
Publicado em 2020-12-01

Rivaroxaban in patients with atrial fibrillation: from research to real practice (based on REGistry of Long-term AnTithrombotic TherApy-2 (REGATA))

Por E. S. Kropacheva, E. N. Krivosheeva, E. P. Panchenko
Publicado em 2021-07-01

CLINICAL FACTORS AND ANTICOAGULATION LEVEL THAT DETERMINE THE SUDDEN LOSS OF KIDNEY FUNCTION IN PATIENTS LONG-TAKING WARFARIN (A 5-YEAR PROSPECTIVE, OBSERVATIONAL STUDY)

Por E. S. Kropacheva, O. A. Zemlyanskaya, A. В. Dobrovolsky, Е. P. Panchenko
Publicado em 2018-05-01

THE EFFICACY OF LONG-TERM WARFARIN THERAPY: THE IMPACT ON THE INCIDENCE OF ISCHEMIC CEREBROVASCULAR DISORDERS AND CLINICAL PREDICTORS OF DEVELOPING SUCH DISORDERS. (Results of a pr...

Por E. S. KROPACHEVA, O. A. ZEMLYANSKAYA, A. B. DOBROVOLSKY, E. P. PANCHENKO
Publicado em 2017-12-01

Comparative efficacy and safety of enoxaparin followed by warfarin and rivaroxaban monotherapy in the treatment of venous thrombosis in patients after intracardiac catheter interve...

Por A I Loginova, E S Kropacheva, E B Maykov, T V Balakhonova, S P Golitsyn
Publicado em 2019-09-01

Growth differentiation factor 15 and the risk of cardiovascular events in patients with atrial fibrillation after elective percutaneous coronary intervention

Por E. N. Krivosheeva, E. S. Kropacheva, A. B. Dobrovolsky, E. V. Titaeva, E. P. Panchenko
Publicado em 2021-08-01

SAFETY OF LONG-TERM THERAPY WITH WARFARIN: HEMORRHAGE FREQUENCY AND CLINICAL PREDICTORS (results of a prospective 15-year follow-up)

Por E. S. Kropacheva, O. A. Zemlyanskaya, E. P. Panchenko, A. B. Dobrovolsky, E. N. Krivosheeva
Publicado em 2017-05-01

2020 Clinical guidelines for Atrial fibrillation and atrial flutter

Por M. G. Arakelyan, L. A. Bockeria, E. Yu. Vasilieva, S. P. Golitsyn, E. Z. Golukhova, M. V. Gorev, K. V. Davtyan, O. M. Drapkina, E. S. Kropacheva, E. A. Kuchinskaya, L. Yu. Lajovich, N. Yu. Mironov, I. E. Mishina, E. P. Panchenko, A. Sh. Revishvili, F. G. Rzayev, B. A. Tatarsky, M. D. Utsumueva, O. O. Shakhmatova, N. B. Shlevkov, A. V. Shpektor, D. A. Andreev, E. A. Artyukhina, O. L. Barbarash, A. S. Galyavich, D. V. Duplyakov, S. A. Zenin, D. S. Lebedev, E. N. Mikhailov, N. A. Novikova, S. V. Popov, A. G. Filatov, E. V. Shlyakhto, Yu. V. Shubik
Publicado em 2021-08-01